Aldose reductase, ocular diabetic complications and the development of topical Kinostat®

Progress in Retinal and Eye Research

Volumn 54, Issue , 2016, Pages 1-29

  Kador, Peter F ^a,b   Wyman, Milton ^b,c   Oates, Peter J ^d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Therapeutic Vision Inc   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Oates Biomedical Consulting LLC   (United States)

Author keywords

Aldose reductase inhibitor; Diabetic cataract; Diabetic keratopathy; Diabetic retinopathy; Kinostat

Indexed keywords

2 METHYLSORBINIL; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; GALACTOSE; SORBINIL; ZENARESTAT; ENZYME INHIBITOR; EYE DROPS; IMIDAZOLIDINE DERIVATIVE;

CARBOHYDRATE DIET; CATARACT; CATARACTOGENESIS; CLINICAL EVALUATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; KERATOPATHY; LONG TERM CARE; NONHUMAN; PATHOGENESIS; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CORNEA DISEASE; DIABETIC COMPLICATION; METABOLISM; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ALDEHYDE REDUCTASE; ANIMALS; CATARACT; CORNEAL DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENZYME INHIBITORS; HUMANS; IMIDAZOLIDINES; OPHTHALMIC SOLUTIONS;

EID: 84965076002     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2016.04.006     Document Type: Review

References (257)

1. Abdelkader, H., Patel, D.V., McGhee, C., Alany, R.G., New therapeutic approaches in the treatment of diabetic keratopathy: a review. Clin. Exp. Ophthalmol. 39 (2011), 259–270.
2. Ai, Y., Zheng, Z., O'Brien-Jenkins, A., Bernard, D.J., Wynshaw-Boris, T., Ning, C., Reynolds, R., Segal, S., Huang, K., Stambolian, D., A mouse model of galactose-induced cataracts. Hum. Mol. Genet. 9 (2000), 1821–1827.
3. Akagi, Y., Kador, P.F., Kinoshita, J.H., Immunohistochemical localization for aldose reductase in diabetic lenses. Invest. Ophthalmol. Vis. Sci. 28 (1987), 163–167.
4. Akagi, Y., Kador, P.F., Kuwabara, T., Kinoshita, J.H., Aldose reductase localization in human retinal mural cells. Invest. Ophthalmol. Vis. Sci. 24 (1983), 1516–1519.
5. Akagi, Y., Tasaka, H., Terubayashi, H., Kador, P.F., Kinoshita, J.H., Aldose Reductase Localization in Rat Sugar Cataracts. 1986, Exerpta Medica, Amsterdam.
6. Akagi, Y., Terubayashi, H., Ikebe, H., Kador, P.F., Kinoshita, J.H., Repair of Corneal Endothelium in Galactosemic Rats. 1986, Exerpta Medica, Amsterdam.
7. Akagi, Y., Terubayashi, H., Millen, J., Kador, P.F., Kinoshita, J.H., Aldose reductase localization in dog retinal mural cells. Curr. Eye Res. 5 (1986), 883–886.
8. Akagi, Y., Yajima, Y., Kador, P.F., Kuwabara, T., Kinoshita, J.H., Localization of aldose reductase in the human eye. Diabetes 33 (1984), 562–566.
9. American Veterinary Medical Association, U.S. Pet Ownership and Demographics Sourcebook. 2012, American Veterinary Medical Association.
10. Anderson, H.R., Stitt, A.W., Gardiner, T.A., Lloyd, S.J., Archer, D.B., Induction of alloxan/streptozotocin diabetes in dogs: a revised experimental technique. Lab. Anim. 27 (1993), 281–285.
11. Antonetti, D.A., Barber, A.J., Bronson, S.K., Freeman, W.M., Gardner, T.W., Jefferson, L.S., Kester, M., Kimball, S.R., Krady, J.K., LaNoue, K.F., Norbury, C.C., Quinn, P.G., Sandirasegarane, L., Simpson, I.A., Group, J.D.R.C., Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55 (2006), 2401–2411.
12. Antonetti, D.A., Klein, R., Gardner, T.W., Diabetic retinopathy. N. Engl. J. Med. 366 (2012), 1227–1239.
13. Aronson, D., Hyperglycemia and the pathobiology of diabetic complications. Adv. Cardiol. 45 (2008), 1–16.
14. Astle, W.F., Alewenah, O., Ingram, A.D., Paszuk, A., Surgical outcomes of primary foldable intraocular lens implantation in children: understanding posterior opacification and the absence of glaucoma. J. Cataract. Refract Surg. 35 (2009), 1216–1222.
15. Awan, A., Saboor, T., Buchanan, L.M., Acute irreversible diabetic cataract in adolescence: a case report. Eye 20 (2005), 398–400.
16. Awata, T., Matsuda, M., Ohashi, Y., Fukuda, M., The Effect of Topical Aldose Reductase Inhibitor on Diabetic Keratopathy. 1990, Exerpta Medica, Amsterdam.
17. Awata, T., Sogo, S., Yamagami, Y., Yamamoto, Y., Effect of an aldose reductase inhibitor, CT-112, on healing of the corneal epithelium in galactose-fed rats. J. Ocul. Pharmacol. 4 (1988), 195–201.
18. Awata, T., Sogo, S., Yamamoto, Y., Effects of aldose reductase inhibitor, CT-112, on sugar alcohol accumulation in corneal epithelium of galactose-fed rats. Jpn. J. Ophthalmol. 30 (1986), 245–250.
19. Barnett, P.A., Gonzalez, R.G., Chylack, L.T. Jr., Cheng, H.M., The effect of oxidation on sorbitol pathway kinetics. Diabetes 35 (1986), 426–432.
20. Beam, S., Correa, M.T., Davidson, M.G., A retrospective-cohort study on the development of cataracts in dogs with diabetes mellitus: 200 cases. Vet. Ophthalmol. 2 (1999), 169–172.
21. Bettelheim, F.A., Li, L., Zeng, F.F., Do changes in the hydration of the diabetic human lens precede cataract formation?. Res. Commun. Mol. Pathol. Pharmacol. 102 (1998), 3–14.
22. Beyer-Mears, A., Cruz, E., Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor. Diabetes 34 (1985), 15–21.
23. Beyer-Mears, A., Cruz, E., Varagiannis, E., Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor. Pharmacology 31 (1985), 88–96.
24. Beyer-Mears, A., Diecke, F.P., Mistry, K., Ellison, C., Cruz, E., Effect of pyruvate on lens myo-inositol transport and polyol formation in diabetic cataract. Pharmacology 55 (1997), 78–86.
25. Broadwater, J.J., Colitz, C., Carastro, S., Saville, W., Tear production in normal juvenile dogs. Vet. Ophthalmol. 13 (2010), 321–325.
26. Bron, A.J., Brown, N.A., Harding, J.J., Ganea, E., The lens and cataract in diabetes. Int. Ophthalmol. Clin. 38 (1998), 37–67.
27. Bron, A.J., Sparrow, J., Brown, N.A., Harding, J.J., Blakytny, R., The lens in diabetes. Eye 7:Pt 2 (1993), 260–275.
28. Brown, M.J., Bird, S.J., Watling, S., Kaleta, H., Hayes, L., Eckert, S., Foyt, H.L., Zenarest, s, Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care 27 (2004), 1153–1159.
29. Buzney, S.M., Frank, R.N., Varma, S.D., Tanishima, T., Gabbay, K.H., Aldose reductase in retinal mural cells. Invest. Ophthalmol. Vis. Sci. 16 (1977), 392–396.
30. Cameron, N.E., Cotter, M.A., Dines, K.C., Maxfield, E.K., Carey, F., Mirrlees, D.J., Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 37 (1994), 651–663.
31. Catchpole, B., Canine Diabetes Mellitus. 2007, Society for Endocrinology BES 2007,. Endocrine Abstracts, Birmingham, UK, S35.
32. Cheng, H.M., Gonzalez, R.G., The effect of high glucose and oxidative stress on lens metabolism, aldose reductase, and senile cataractogenesis. Metabolism 35 (1986), 10–14.
33. Cheng, H.M., Gonzalez, R.G., Barnett, P.A., Aguayo, J.B., Wolfe, J., Chylack, L.T. Jr., Sorbitol/fructose metabolism in the lens. Exp. Eye Res. 40 (1985), 223–229.
34. Cheung, A.K., Fung, M.K., Lo, A.C., Lam, T.T., So, K.F., Chung, S.S., Chung, S.K., Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 54 (2005), 3119–3125.
35. Chiou, G.C., Systemic delivery of polypeptide drugs through ocular route. J. Ocul. Pharmacol. 10 (1994), 93–99.
36. Chiou, S.H., Chylack, L.T. Jr., Bunn, H.F., Kinoshita, J.H., Role of nonenzymatic glycosylation in experimental cataract formation. Biochem. Biophys. Res. Commun. 95 (1980), 894–901.
37. Chylack, L.T. Jr., Henriques, H.F. 3rd, Cheng, H.M., Tung, W.H., Efficacy of Alrestatin, an aldose reductase inhibitor, in human diabetic and nondiabetic lenses. Ophthalmology 86 (1979), 1579–1585.
38. Chylack, L.T. Jr., Kinoshita, J.H., A biochemical evaluation of a cataract induced in a high-glucose medium. Invest. Ophthalmol. 8 (1969), 401–412.
39. Chylack, L.T. Jr., Tung, W., Harding, R., Sorbitol production in the lens: a means of counteracting glucose-derived osmotic stress. Ophthalmic Res. 18 (1986), 313–320.
40. Cisarik-Fredenburg, P., Discoveries in research on diabetic keratopathy. Optometry 72 (2001), 691–704.
41. Cogan, D.G., Kinoshita, J.H., Kador, P.F., Robison, G., Datilis, M.B., Cobo, L.M., Kupfer, C., NIH conference. Aldose reductase and complications of diabetes. Ann. Intern Med. 101 (1984), 82–91.
42. Cogan, D.G., Kuwabara, T., The mural cell in perspective. Archives Ophthalmol. 78 (1967), 133–139.
43. Cusick, M., Chew, E.Y., Ferris, F. 3rd, Cox, T.A., Chan, C.C., Kador, P.F., Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Archives Ophthalmol. 121 (2003), 1745–1751.
44. Dabelea, D., The accelerating epidemic of childhood diabetes. Lancet 373 (2009), 1999–2000.
45. Dabelea, D., Bell, R.A., D'Agostino, R.B. Jr., Imperatore, G., Johansen, J.M., Linder, B., Liu, L.L., Loots, B., Marcovina, S., Mayer-Davis, E.J., Pettitt, D.J., Waitzfelder, B., Incidence of diabetes in youth in the United States. JAMA 297 (2007), 2716–2724.
46. Dagher, Z., Park, Y.S., Asnaghi, V., Hoehn, T., Gerhardinger, C., Lorenzi, M., Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 53 (2004), 2404–2411.
47. Datiles, M.B., Kador, P.F., Fukui, H.N., Hu, T.S., Kinoshita, J.H., Corneal re-epithelialization in galactosemic rats. Invest. Ophthalmol. Vis. Sci. 24 (1983), 563–569.
48. Datiles, M.B., Kador, P.F., Kashima, K., Kinoshita, J.H., Sinha, A., The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs. Invest. Ophthalmol. Vis. Sci. 31 (1990), 2201–2204.
49. Datta, V., Swift, P.G., Woodruff, G.H., Harris, R.F., Metabolic cataracts in newly diagnosed diabetes. Arch. Dis. Child. 76 (1997), 118–120.
50. Davidson, E.P., Coppey, L.J., Holmes, A., Lupachyk, S., Dake, B.L., Oltman, C.L., Peterson, R.G., Yorek, M.A., Characterization of diabetic neuropathy in the Zucker diabetic Sprague-Dawley rat: a new animal model for type 2 diabetes. J. diabetes Res., 2014, 2014, 714273.
51. Demaine, A., Cross, D., Millward, A., Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest. Ophthalmol. Vis. Sci. 41 (2000), 4064–4068.
52. Demaine, A.G., Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr. Med. Chem. 10 (2003), 1389–1398.
53. Diabetes Complications Control Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Diabetes control and complications trial research group. Ophthalmology 102 (1995), 647–661.
54. dos Santos, K.G., Canani, L.H., Gross, J.L., Tschiedel, B., Souto, K.E., Roisenberg, I., The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes. Mol. Genet. Metab. 88 (2006), 280–284.
55. Engerman, R., Bloodworth, J.M. Jr., Nelson, S., Relationship of microvascular disease in diabetes to metabolic control. Diabetes 26 (1977), 760–769.
56. Engerman, R.L., Bloodworth, J.M. Jr., Experimental diabetic retinopathy in dogs. Archives Ophthalmol. 73 (1965), 205–210.
57. Engerman, R.L., Kern, T.S., Experimental galactosemia produces diabetic-like retinopathy. Diabetes 33 (1984), 97–100.
58. Engerman, R.L., Kern, T.S., Retinopathy in galactosemic dogs continues to progress after cessation of galactosemia. Arch. Ophthalmol. 113 (1995), 355–358.
59. Esteves, J.F., Dal Pizzol, M.M., Sccoco, C.A., Roggia, M.F., Milano, S.B., Guarienti, J.A., Rodrigues, T.C., Canani, L.H., Cataract and type 1 diabetes mellitus. Diabetes Res. Clin. Pract. 82 (2008), 324–328.
60. Feman, S.S., Leonard-Martin, T.C., Redman, J.R., The Vanderbilt Classification System in the evaluation of diabetic retinopathy patients treated with Alredase. Trans. Am. Ophthalmol. Soc. 94 (1996), 433–447 discussion 447–450.
61. Ferris, F.L. III, Emerging therapies for diabetic retinopathy. Johns Hopkins Adv. Stud. Ophthalmol., 2, 2005, 26030.
62. Florkowski, A.R., Golden, R., Sooch, Y., Krishna, R., Sudden bilateral visual loss in a diabetic man. Am. J. Med. Sci. 329 (2005), 99–101.
63. Florys, B., Oldytowska, A., Glowinska, B., Peczynska, J., Urban, M., Prevalence of chronic diabetes complications depending on the method of insulin therapy in children and adolescents with type 1 diabetes. Endokrynol. Diabetol. Chor. Przemiany Materii Wieku Rozw. 10 (2004), 31–39.
64. Foulks, G.N., Thoft, R.A., Perry, H.D., Tolentino, F.I., Factors related to corneal epithelial complications after closed vitrectomy in diabetics. Arch. Ophthalmol. 97 (1979), 1076–1078.
65. Frank, R.N., Keirn, R.J., Kennedy, A., Frank, K.W., Galactose-induced retinal capillary basement membrane thickening: prevention by Sorbinil. Invest. Ophthalmol. Vis. Sci. 24 (1983), 1519–1524.
66. Friedenwald, J.S., Rytel, D., Contributions to histopathology of cataract. Arch. Ophthalmol. 53 (1955), 825–831.
67. Fujisawa, T., Ikegami, H., Kawaguchi, Y., Yamato, E., Nakagawa, Y., Shen, G.Q., Fukuda, M., Ogihara, T., Length rather than a specific allele of dinucleotide repeat in the 5’ upstream region of the aldose reductase gene is associated with diabetic retinopathy. Diabet. Med. 16 (1999), 1044–1047.
68. Fujishima, H., Shimazaki, J., Yagi, Y., Tsubota, K., Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study. Cornea 15 (1996), 368–375.
69. Fujishima, H., Tsubota, K., Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235. Br. J. Ophthalmol. 86 (2002), 860–863.
70. Fukushi, S., Merola, L.O., Tanaka, M., Datiles, M., Kinoshita, J.H., Reepithelialization of denuded corneas in diabetic rats. Exp. Eye Res. 31 (1980), 611–621.
71. Gelatt, K.N., Spontaneous cataract resorption and lens-induced uveitis in the dog. Mod. Vet. Pract. 56 (1975), 331–335.
72. Gella, L., Raman, R., Pal, S.S., Ganesan, S., Sharma, T., Incidence, progression, and associated risk factors of posterior vitreous detachment in type 2 diabetes mellitus: sankara nethralaya diabetic retinopathy epidemiology and molecular genetic study (SN-DREAMS II, report No. 7). Semin. Ophthalmol., 1–7, 2015.
73. Gelvin, J.B., Thonn, V.A., The formation and reversal of acute cataracts in diabetes mellitus. J. Am. Optom. Assoc. 64 (1993), 471–474.
74. Geraldes, P., King, G.L., Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res. 106 (2010), 1319–1331.
75. Giacco, F., Du, X., Carratu, A., Gerfen, G.J., D'Apolito, M., Giardino, I., Rasola, A., Marin, O., Divakaruni, A.S., Murphy, A.N., Shah, M.S., Brownlee, M., GLP-1 cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop. Diabetes 64 (2015), 3273–3284.
76. Gonzalez, A.M., Sochor, M., McLean, P., The effect of an aldose reductase inhibitor (Sorbinil) on the level of metabolites in lenses of diabetic rats. Diabetes 32 (1983), 482–485.
77. Greene, D.A., Arezzo, J.C., Brown, M.B., Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 53 (1999), 580–591.
78. Grossniklaus, H.E., Kang, S.J., Berglin, L., Animal models of choroidal and retinal neovascularization. Prog. Retin Eye Res. 29 (2010), 500–519.
79. Guo, C., Zhang, Z., Zhang, P., Makita, J., Kawada, H., Blessing, K., Kador, P.F., Novel transgenic mouse models develop retinal changes associated with early diabetic retinopathy similar to those observed in rats with diabetes mellitus. Exp. Eye Res. 119 (2014), 77–87.
80. Guptill, L., Glickman, L., Glickman, N., Time trends and risk factors for diabetes mellitus in dogs: analysis of veterinary medical data base records (1970-1999). Vet. J. 165 (2003), 240–247.
81. Haddad, N.M., Sun, J.K., Abujaber, S., Schlossman, D.K., Silva, P.S., Cataract surgery and its complications in diabetic patients. Semin. Ophthalmol. 29 (2014), 329–337.
82. Hamada, Y., Araki, N., Horiuchi, S., Hotta, N., Role of polyol pathway in nonenzymatic glycation. Nephrol. Dial. Transpl. 11:Suppl. 5 (1996), 95–98.
83. Harding, J.J., Pharmacological treatment strategies in age-related cataracts. Drugs Aging 2 (1992), 287–300.
84. Hasuike, Y., Nakanishi, T., Otaki, Y., Nanami, M., Tanimoto, T., Taniguchi, N., T, Y., Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes. Am. J. Kidney Dis. 40 (2002), 464–471.
85. Hathout, E.H., Hartwick, N., Fagoaga, O.R., Colacino, A.R., Sharkey, J., Racine, M., Nelsen-Cannarella, S., Mace, J.W., Clinical, autoimmune, and HLA characteristics of children diagnosed with type 1 diabetes before 5 years of age. Pediatrics 111 (2003), 860–863.
86. Heesom, A.E., Hibberd, M.L., Millward, A., Demaine, A.G., Polymorphism in the 5’-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 46 (1997), 287–291.
87. Ho, E.C., Lam, K.S., Chen, Y.S., Yip, J.C., Arvindakshan, M., Yamagishi, S., Yagihashi, S., Oates, P.J., Ellery, C.A., Chung, S.S., Chung, S.K., Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 55 (2006), 1946–1953.
88. Hohman, T.C., Nishimura, C., Robison, W.G. Jr., Aldose reductase and polyol in cultured pericytes of human retinal capillaries. Exp. Eye Res. 48 (1989), 55–60.
89. Hosotani, H., Ohashi, Y., Kinoshita, S., Matsumoto, T., Awata, T., Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats. Curr. Eye Res. 15 (1996), 1005–1007.
90. Hosotani, H., Ohashi, Y., Yamada, M., Tsubota, K., Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am. J. Ophthalmol. 119 (1995), 288–294.
91. Hosotani, H., Tano, Y., Tamada, R., Treatment of diabetic keratopathy with a topical aldose reductase inhibitor. Olia Jpn. Ophthalmol. Clinica 37 (1986), 1359–1365.
92. Hu, T.S., Datiles, M., Kinoshita, J.H., Reversal of galactose cataract with Sorbinil in rats. Invest. Ophthalmol. Vis. Sci. 24 (1983), 640–644.
93. Hussin, H.M., Markham, R., Long-term visual function outcomes of congenital cataract surgery with intraocular lens implantation in children under 5 years of age. Eur. J. Ophthalmol. 19 (2009), 754–761.
94. Ibaraki, N., Chen, S.C., Lin, L.R., Okamoto, H., Pipas, J.M., Reddy, V.N., Human lens epithelial cell line. Exp. Eye Res. 67 (1998), 577–585.
95. Ichikawa, F., Yamada, K., Ishiyama-Shigemoto, S., Yuan, X., Nonaka, K., Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5’-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus. Diabet. Med. 16 (1999), 744–748.
96. Ikegishi, Y., Tawata, M., Aida, K., Onaya, T., Z-4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro. Life Sci. 65 (1999), 2061–2070.
97. Jacot, J.L., Hosotani, H., Glover, J.P., Lois, N., Robison, W.G. Jr., Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors. J. Ocul. Pharmacol. Ther. 14 (1998), 169–180.
98. Jedziniak, J.A., Chylack, L.T. Jr., Cheng, H.M., Gillis, M.K., Kalustian, A.A., Tung, W.H., The sorbitol pathway in the human lens: aldose reductase and polyol dehydrogenase. Invest. Ophthalmol. Vis. Sci. 20 (1981), 314–326.
99. Jha, J.C., Gray, S.P., Barit, D., Okabe, J., El-Osta, A., Namikoshi, T., Thallas-Bonke, V., Wingler, K., Szyndralewiez, C., Heitz, F., Touyz, R.M., Cooper, M.E., Schmidt, H.H., Jandeleit-Dahm, K.A., Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J. Am. Soc. Nephrol. 25 (2014), 1237–1254.
100. Kador, P.F., Prevention of ocular diabetic complications by aldose reductase inhibitors. Swiss Pharma 12 (1990), 33–38.
101. Kador, P.F., Ocular pathology of diabetes mellitus. Tasman, W., Jaeger, E., (eds.) Duane's Ophthalmology, 2007, Wolters Kluwer/Lippicott Williams and Wilkins, Philadelphia, 1–84.
102. Kador, P.F., Diabetes-associated Cataracts. 2010, Saunders Elsevier.
103. Kador, P.F., Akagi, Y., Kinoshita, J.H., The effect of aldose reductase and its inhibition on sugar cataract formation. Metabolism 35 (1986), 15–19.
104. Kador, P.F., Akagi, Y., Takahashi, Y., Ikebe, H., Wyman, M., Kinoshita, J.H., Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Archives Ophthalmol. 108 (1990), 1301–1309.
105. Kador, P.F., Akagi, Y., Terubayashi, H., Wyman, M., Kinoshita, J.H., Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Archives Ophthalmol. 106 (1988), 1099–1102.
106. Kador, P.F., Betts, D., Wyman, M., Blessing, K., Randazzo, J., Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose. Am. J. Vet. Res. 67 (2006), 1783–1787.
107. Kador, P.F., J.S, Z., Clark, J., Datiles, M.i.D.s.O.T.W.a.J.E., (eds.) On DVD-ROM Medical Treatment of Cataracts, 2010, Lippincott Williams & Wilkins, 2010, Philadelphia (Lippincott Williams & Wilkins, Philadelphia).
108. Kador, P.F., Kinoshita, J.H., Diabetic and galactosaemic cataracts. Ciba Found. Symp. 106 (1984), 110–131.
109. Kador, P.F., Lee, J.W., Fujisawa, S., Blessing, K., Lou, M.F., Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats. J. Ocul. Pharmacol. Ther. 16 (2000), 149–160.
110. Kador, P.F., Randazzo, J., Babb, T., Koushik, K., Takamura, Y., Zhu, W., Blessing, K., Kompella, U.B., Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J. Ocul. Pharmacol. Ther. 23 (2007), 116–123.
111. Kador, P.F., Takahashi, Y., Akagi, Y., Blessing, K., Randazzo, J., Wyman, M., Age-dependent retinal capillary pericyte degeneration in galactose-fed dogs. J. Ocul. Pharmacol. Ther. 23 (2007), 63–69.
112. Kador, P.F., Takahashi, Y., Akagi, Y., Neuenschwander, H., Greentree, W., Lackner, P., Blessing, K., Wyman, M., Effect of galactose diet removal on the progression of retinal vessel changes in galactose-fed dogs. Invest. Ophthalmol. Vis. Sci. 43 (2002), 1916–1921.
113. Kador, P.F., Takahashi, Y., Sato, S., Wyman, M., Amelioration of diabetes-like retinal changes in galactose-fed dogs. Prev. Med. 23 (1994), 717–721.
114. Kador, P.F., Takahashi, Y., Wyman, M., Ferris, F. 3rd, Diabeteslike proliferative retinal changes in galactose-fed dogs. Archives Ophthalmol. 113 (1995), 352–354.
115. Kador, P.F., Takahashi, Y., Wyman, M., K, J.H., The role of aldose reductase in retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs. National Eye Institute – Juvenile Diabetes Foundation Workshop on Aldose Reductase Inhibitors, 1990, Department of Health and Human Services, Bethesda, MD, 75–107.
116. Kador, P.F., Webb, T.R., Bras, D., Ketring, K., Wyman, M., Topical KINOSTAT ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus. Vet. Ophthalmol. 13 (2010), 363–368.
117. Kador, P.F., Zhang, P., Makita, J., Zhang, Z., Guo, C., Randazzo, J., Kawada, H., Haider, N., Blessing, K., Novel diabetic mouse models as tools for investigating diabetic retinopathy. PLoS One, 7, 2012, e49422.
118. Kaji, Y., Prevention of diabetic keratopathy. Br. J. Ophthalmol. 89 (2005), 254–255.
119. Kandarakis, S.A., Piperi, C., Topouzis, F., Papavassiliou, A.G., Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog. Retin Eye Res. 42 (2014), 85–102.
120. Kao, Y.L., Donaghue, K., Chan, A., Knight, J., Silink, M., An aldose reductase intragenic polymorphism associated with diabetic retinopathy. Diabetes Res. Clin. Pract. 46 (1999), 155–160.
121. Karampatakis, V., Karamitsos, A., Skriapa, A., Pastiadis, G., Comparison between normal values of 2- and 5-minute Schirmer test without anesthesia. Cornea 29 (2010), 497–501.
122. Kennedy, A., Frank, R.N., Varma, S.D., Aldose reductase activity in retinal and cerebral microvessels and cultured vascular cells. Invest. Ophthalmol. Vis. Sci. 24 (1983), 1250–1258.
123. Kern, T.S., Dog model for diabetic retinopathy and nephropathy. National Eye Institute – Juvenile Diabetes Foundation Workshop on Aldose Reductase Inhibitors, 1990, Department of Health and Human Services, Bethesda, MD, 65–72.
124. Kern, T.S., Engerman, R.L., Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor. Invest. Ophthalmol. Vis. Sci. 32 (1991), 3175–3177.
125. Kern, T.S., Tang, J., Berkowitz, B.A., Validation of structural and functional lesions of diabetic retinopathy in mice. Mol. Vis. 16 (2010), 2121–2131.
126. Kinoshita, J.H., Cataracts in galactosemia. The Jonas S. Friedenwald memorial lecture. Invest. Ophthalmol. 4 (1965), 786–799.
127. Kinoshita, J.H., Mechanisms initiating cataract formation. Proctor Lecture. Invest. Ophthalmol. 13 (1974), 713–724.
128. Kinoshita, J.H., Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture. Am. J. Ophthalmol. 102 (1986), 685–692.
129. Kinoshita, J.H., Barber, G.W., Merola, L.O., Tung, B., Changes in the levels of free amino acids and myo-inositol in the galactose-exposed lens. Invest. Ophthalmol. 8 (1969), 625–632.
130. Kinoshita, J.H., Fukushi, S., Kador, P., Merola, L.O., Aldose reductase in diabetic complications of the eye. Metabolism 28 (1979), 462–469.
131. Kinoshita, J.H., Futterman, S., Satoh, K., Merola, L.O., Factors affecting the formation of sugar alcohols in ocular lens. Biochim. Biophys. Acta 74 (1963), 340–350.
132. Kinoshita, J.H., Kador, P., Datiles, M., Aldose reductase in diabetic cataracts. Jama 246 (1981), 257–261.
133. Kinoshita, J.H., Merola, L.O., Hayman, S., Osmotic effects on the amino acid-concentrating mechanism in the rabbit lens. J. Biol. Chem. 240 (1965), 310–315.
134. Kinoshita, J.H., Merola, L.O., Tung, B., Changes in cation permeability in the galactose–exposed rabbit lens. Exp. Eye Res. 7 (1968), 80–90.
135. Klein, H.E., Krohne, S.G., Moore, G.E., Stiles, J., Postoperative complications and visual outcomes of phacoemulsification in 103 dogs (179 eyes): 2006-2008. Vet. Ophthalmol. 14 (2011), 114–120.
136. Ko, B.C., Lam, K.S., Wat, N.M., Chung, S.S., An (A-C)n dinucleotide repeat polymorphic marker at the 5’ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 44 (1995), 727–732.
137. Kowluru, R.A., Zhong, Q., Kanwar, M., Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp. Eye Res. 90 (2010), 617–623.
138. Kubo, E., Nakamura, S., Tsuzuki, S., Takahashi, Y., Akagi, Y., Mizuno, K., Matsubara, A., Inhibitory effect of orally administered aldose reductase inhibitor SNK-860 on corneal polyol accumulation in galactose-fed rats. Graefes Arch. Clin. Exp. Ophthalmol. 237 (1999), 758–762.
139. Kubo, E., Urakami, T., Fatma, N., Akagi, Y., Singh, D.P., Polyol pathway-dependent osmotic and oxidative stresses in aldose reductase-mediated apoptosis in human lens epithelial cells: role of AOP2. Biochem. Biophys. Res. Commun. 314 (2004), 1050–1056.
140. Kumamoto, Y., Takamura, Y., Kubo, E., Tsuzuki, S., Akagi, Y., Epithelial cell density in cataractous lenses of patients with diabetes: association with erythrocyte aldose reductase. Exp. Eye Res. 85 (2007), 393–399.
141. Kumaramanickavel, G., Sripriya, S., Ramprasad, V.L., Upadyay, N.K., Paul, P.G., Sharma, T., Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic Genet. 24 (2003), 41–48.
142. Kuwabara, T., Kinoshita, J.H., Cogan, D.G., Electron microscopic study of galactose-induced cataract. Invest. Ophthalmol. 8 (1969), 133–149.
143. Lackner, P.A., Rodriguez, L., Sato, S., Lizak, M.J., Wyman, M., Kador, P.F., Age-dependent lens changes in galactose-fed dogs. Exp. Eye Res. 64 (1997), 431–436.
144. Lang-Muritano, M., La Roche, G.R., Stevens, J.L., Gloor, B.R., Schoenle, E.J., Acute cataracts in newly diagnosed IDDM in five children and adolescents. Diabetes Care 18 (1995), 1395–1396.
145. Lee, A.Y., Chung, S.K., Chung, S.S., Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 2780–2784.
146. Lee, A.Y., Chung, S.S., Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 13 (1999), 23–30.
147. Lee, S.C., Wang, Y., Ko, G.T., Critchley, J.A., Ng, M.C., Tong, P.C., Cockram, C.S., Chan, J.C., Association of retinopathy with a microsatellite at 5’ end of the aldose reductase gene in Chinese patients with late-onset Type 2 diabetes. Ophthalmic Genet. 22 (2001), 63–67.
148. Lee, S.C., Wang, Y., Ko, G.T., Ma, R.C., Critchley, J.A., Cockram, C.S., Chan, J.C., Risk factors for cataract in Chinese patients with type 2 diabetes: evidence for the influence of the aldose reductase gene. Clin. Genet. 59 (2001), 356–359.
149. Lerman, S., Moran, M., Sorbitol generation and its inhibition by Sorbinil in the aging normal human and rabbit lens and human diabetic cataracts. Ophthalmic Res. 20 (1988), 348–352.
150. Lim, C.C., Bakker, S.C., Waldner, C.L., Sandmeyer, L.S., Grahn, B.H., Cataracts in 44 dogs (77 eyes): a comparison of outcomes for no treatment, topical medical management, or phacoemulsification with intraocular lens implantation. Can. Vet. J. 52 (2011), 283–288.
151. Lizak, M.J., Mori, K., Ceckler, T.L., Balaban, R.S., Kador, P.F., Quantitation of galactosemic cataracts in dogs using magnetization transfer contrast-enhanced magnetic resonance imaging. Invest. Ophthalmol. Vis. Sci. 37 (1996), 2219–2227.
152. Lizak, M.J., Secchi, E.F., Lee, J.W., Sato, S., Kubo, E., Akagi, Y., Kador, P.F., 3-FG as substrate for investigating flux through the polyol pathway in dog lens by 19F-NMR spectroscopy. Invest. Ophthalmol. Vis. Sci. 39 (1998), 2688–2695.
153. Lorenzi, M., O, P.J., The polyol pathway and diabetic retinopathy. E, D., (eds.) Diabetic Retinopathy Totowa, NJ, 2008, 159–186.
154. Malone, J.I., Leavengood, H., Peterson, M.J., O'Brien, M.M., Page, M.G., Aldinger, C.E., Red blood cell sorbitol as an indicator of polyol pathway activity. Inhibition by sorbinil in insulin-dependent diabetic subjects. Diabetes 33 (1984), 45–49.
155. Maret, W., Auld, D.S., Purification and characterization of human liver sorbitol dehydrogenase. Biochemistry 27 (1988), 1622–1628.
156. Marmor, M., Willeberg, P., Glickman, L.T., Priester, W.A., Cypess, R.H., Hurvitz, A.I., Epizootiologic patterns of diabetes mellitus in dogs. Am. J. Vet. Res. 43 (1982), 465–470.
157. Mathew, B., Worldwide Prevalence of Diabetes. 2010 healthguideinfo.com.
158. Matsuda, M., Awata, T., Ohashi, Y., Inaba, M., Fukuda, M., Manabe, R., The effects of aldose reductase inhibitor on the corneal endothelial morphology in diabetic rats. Curr. Eye Res. 6 (1987), 391–397.
159. Meyer, L.A., Ubels, J.L., Edelhauser, H.F., Corneal endothelial morphology in the rat. Effects of aging, diabetes, and topical aldose reductase inhibitor treatment. Invest. Ophthalmol. Vis. Sci. 29 (1988), 940–948.
160. Miyamoto, N., de Kozak, Y., Jeanny, J.C., Glotin, A., Mascarelli, F., Massin, P., BenEzra, D., Behar-Cohen, F., Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 50 (2007), 461–470.
161. Miyazawa, T., Kubo, E., Takamura, Y., Akagi, Y., Up-regulation of P-glycoprotein expression by osmotic stress in rat sugar cataract. Exp. Eye Res. 84 (2007), 246–253.
162. Mizuno, A., Toshima, S., Mori, Y., Confirmation of lens hydration by Raman spectroscopy. Exp. Eye Res. 50 (1990), 647–649.
163. Mori, K., Lizak, M.J., Ceckler, T.L., Balaban, R.S., Kador, P.F., Magnetic resonance imaging of the galactosemic dog eye using magnetization transfer contrast. Curr. Eye Res. 14 (1995), 1035–1040.
164. Mori, K., Takahashi, Y., Akagi, Y., Kador, P.F., Effects of aldose reductase inhibitors on galactose-induced changes in corneal epithelium basal cells and basement membrane: a quantitative analysis on long-term galactose-fed rat corneas. Patil, P.N., Puri, V.N., (eds.) Frontiers of Ocular Pharmacology and Therapeutic, 2002, Allied Publishers PVT Limited, New Dehli.
165. Mulhern, M.L., Madson, C.J., Danford, A., Ikesugi, K., Kador, P.F., Shinohara, T., The unfolded protein response in lens epithelial cells from galactosemic rat lenses. Invest. Ophthalmol. Vis. Sci. 47 (2006), 3951–3959.
166. Mulhern, M.L., Madson, C.J., Kador, P.F., Randazzo, J., Shinohara, T., Cellular osmolytes reduce lens epithelial cell death and alleviate cataract formation in galactosemic rats. Mol. Vis. 13 (2007), 1397–1405.
167. Murata, M., Ohta, N., Fujisawa, S., Tsai, J.Y., Sato, S., Akagi, Y., Takahashi, Y., Neuenschwander, H., Kador, P.F., Selective pericyte degeneration in the retinal capillaries of galactose-fed dogs results from apoptosis linked to aldose reductase-catalyzed galactitol accumulation. J. Diabetes Complicat. 16 (2002), 363–370.
168. Murata, M., Ohta, N., Sakurai, S., Alam, S., Tsai, J., Kador, P.F., Sato, S., The role of aldose reductase in sugar cataract formation: aldose reductase plays a key role in lens epithelial cell death (apoptosis). Chem. Biol. Interact. 130–132 (2001), 617–625.
169. Nakahara, M., Miyata, K., Otani, S., Miyai, T., Nejima, R., Yamagami, S., Amano, S., A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients. Br. J. Ophthalmol. 89 (2005), 266–268.
170. Neuenschwander, H., Julia, C., Wyman, M., Kador, P.F., Endothelial changes in galactose-fed dogs. Curr. Eye Res. 14 (1995), 319–322.
171. Neuenschwander, H., Takahashi, Y., Kador, P.F., Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. J. Ocul. Pharmacol. Ther. 13 (1997), 517–528.
172. Nischal, K.F., Kador, P.F., (eds.) Personal Communication on Surgery on Galactosemic Children, 2009.
173. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M.A., Beebe, D., Oates, P.J., Hammes, H.P., Giardino, I., Brownlee, M., Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (2000), 787–790.
174. O'Brien, P.D., Hinder, L.M., Sakowski, S.A., Feldman, E.L., ER stress in diabetic peripheral neuropathy: a new therapeutic target. Antioxid. Redox Signal 21 (2014), 621–633.
175. Oates, P.J., Polyol pathway and diabetic peripheral neuropathy. Int. Rev. Neurobiol. 50 (2002), 325–392.
176. Oates, P.J., Aldose reductase, still a compelling target for diabetic neuropathy. Curr. Drug Targets 9 (2008), 14–36.
177. Oates, P.J., Mylari, B.L., Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin. Investig. Drugs 8 (1999), 2095–2119.
178. Obazawa, H., Merola, L.O., Kinoshita, J.H., The effects of xylose on the isolated lens. Invest. Ophthalmol. 13 (1974), 204–209.
179. Obrosova, I., Cao, X., Greene, D.A., Stevens, M.J., Diabetes-induced changes in lens antioxidant status, glucose utilization and energy metabolism: effect of DL-alpha-lipoic acid. Diabetologia 41 (1998), 1442–1450.
180. Obrosova, I., Faller, A., Burgan, J., Ostrow, E., Williamson, J.R., Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor. Curr. Eye Res. 16 (1997), 34–43.
181. Obrosova, I.G., How does glucose generate oxidative stress in peripheral nerve?. Int. Rev. Neurobiol. 50 (2002), 3–35.
182. Obrosova, I.G., Drel, V.R., Kumagai, A.K., Szabo, C., Pacher, P., Stevens, M.J., Early diabetes-induced biochemical changes in the retina: comparison of rat and mouse models. Diabetologia 49 (2006), 2525–2533.
183. Obrosova, I.G., Fathallah, L., Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study. Diabetologia 43 (2000), 1048–1055.
184. Obrosova, I.G., Kador, P.F., Aldose reductase/polyol inhibitors for diabetic retinopathy. Curr. Pharm. Biotechnol. 12 (2011), 373–385.
185. Obrosova, I.G., Minchenko, A.G., Vasupuram, R., White, L., Abatan, O.I., Kumagai, A.K., Frank, R.N., Stevens, M.J., Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52 (2003), 864–871.
186. Odem, J., Munzinger, E., Violand, S., Van Morlan, A., Rife, D., Bachrach, B., An infant with combination gene mutations for monogenic diabetes of youth (MODY) 2 and 4, presenting with diabetes mellitus requiring insulin (DMRI) at 8 months of age. Pediatr. Diabetes 10 (2009), 550–553.
187. Ohashi, Y., Mano, T., Umemoto, M., Hositani, H., Tamada, R., Tano, Y., Matsuda, M., Fukuda, M., Manabe, R., The effects of aldose reductase inhibitor (CT-112) on diabetic keratoepitheliopathy. Sakamoto, N., Kinoshita, J.H., kador, P.F., Hotta, N., (eds.) Polyol Pathway and its Role in Diabetic Complications, 1986, Excerpta Medica, Kaskikojima, Japan, 231–236.
188. Ohashi, Y., Matsuda, M., Hosotani, H., Tano, Y., Ishimoto, I., Fukuda, M., Manabe, R., Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy. Am. J. Ophthalmol. 105 (1988), 233–238.
189. Ohguro, N., Matsuda, M., Ohashi, Y., Fukuda, M., Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients. Br. J. Ophthalmol. 79 (1995), 1074–1077.
190. Oka, S., Hsu, C.P., Sadoshima, J., Regulation of cell survival and death by pyridine nucleotides. Circ. Res. 111 (2012), 611–627.
191. Oliver, J.A., Clark, L., Corletto, F., Gould, D.J., A comparison of anesthetic complications between diabetic and nondiabetic dogs undergoing phacoemulsification cataract surgery: a retrospective study. Vet. Ophthalmol. 13 (2010), 244–250.
192. Olmos, P., Acosta, A.M., Schiaffino, R., Diaz, R., Alvarado, D., O'Brien, A., Munoz, X., Arriagada, P., Claro, J.C., Vega, R., Vollrath, V., Velasco, S., Emmerich, M., Maiz, A., Aldose reductase gene polymorphism and rate of appearance of retinopathy in non insulin dependent diabetics. Rev. Med. Chil. 127 (1999), 399–409.
193. Olmos, P., Futers, S., Acosta, A.M., Siegel, S., Maiz, A., Schiaffino, R., Morales, P., Diaz, R., Arriagada, P., Claro, J.C., Vega, R., Vollrath, V., Velasco, S., Emmerich, M., (AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics. Diabetes Res. Clin. Pract. 47 (2000), 169–176.
194. Organization, A.V.M., U.S. Pet Ownership & Demographics Sourcebook. 2007 Edition, 2007, AVMA.
195. Orts Vila, P., Devesa Torregrosa, P., Belmonte Martinez, J., Juvenile Diabetic cataract. A rare finding which lead us to the diagnosis of this illness. Arch. Soc. Esp. Oftalmol. 78 (2003), 389–391.
196. Pacher, P., Szabo, C., Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid. Redox Signal 7 (2005), 1568–1580.
197. Paques, M., Massin, P., Gaudric, A., Growth factors and diabetic retinopathy. Diabetes Metab. 23 (1997), 125–130.
198. Park, H.K., Ahn, C.W., Lee, G.T., Kim, S.J., Song, Y.D., Lim, S.K., Kim, K.R., Huh, K.B., Lee, H.C., (AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 55 (2002), 151–157.
199. Patterson, J.W., Hyperglycemia and galactose cataract. Am. J. Physiol. 165 (1954), 541–543.
200. Patz, A., Maumenee, A.E., Studies on diabetic retinopathy. I. Retinopathy in a dog with spontaneous diabetes mellitus. Am. J. Ophthalmol. 54 (1962), 532–541.
201. Perry, H.D., Foulks, G.N., Thoft, R.A., Tolentino, F.I., Corneal complications after closed vitrectomy through the pars plana. Arch. Ophthalmol. 96 (1978), 1401–1403.
202. Peterson, M.J., Page, M.G., Just, L.J., Aldinger, C.E., Malone, J.I., Applicability of red blood cell sorbitol measurements to monitor the clinical activity of sorbinil. Metabolism 35 (1986), 93–95.
203. PetMD, Diabetes in Dogs. 2011.
204. Petropoulos, I.N., Alam, U., Fadavi, H., Marshall, A., Asghar, O., Dabbah, M.A., Chen, X., Graham, J., Ponirakis, G., Boulton, A.J., Tavakoli, M., Malik, R.A., Rapid automated diagnosis of diabetic peripheral neuropathy with in vivo corneal confocal microscopy. Invest. Ophthalmol. Vis. Sci. 55 (2014), 2071–2078.
205. Petrovic, M.G., Peterlin, B., Hawlina, M., Petrovic, D., Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians. J. Diabetes Complicat. 19 (2005), 70–73.
206. Pfeifer, M.A., Schumer, M.P., Gelber, D.A., Aldose reductase inhibitors: the end of an era or the need for different trial designs?. Diabetes 46:Suppl. 2 (1997), S82–S89.
207. Piatigorsky, J., Fukui, H.N., Kinoshita, J.H., Differential metabolism and leakage of protein in an inherited cataract and a normal lens cultured with ouabain. Nature 274 (1978), 558–562.
208. Polydefkis, M., Arezzo, J., Nash, M., Bril, V., Shaibani, A., Gordon, R.J., Bradshaw, K.L., Junor, R.W., Ranirestat Study, G., Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. J. Peripher Nerv. Syst. 20 (2015), 363–371.
209. Quadrado, M.J., Popper, M., Morgado, A.M., Murta, J.N., Van Best, J.A., Diabetes and corneal cell densities in humans by in vivo confocal microscopy. Cornea 25 (2006), 761–768.
210. Rabbani, N., Thornalley, P.J., Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids 42 (2012), 1133–1142.
211. Rand, J.S., Fleeman, L.M., Farrow, H.A., Appleton, D.J., Lederer, R., Canine and feline diabetes mellitus: nature or nurture?. J. Nutr. 134 (2004), 2072S–2080S.
212. Randazzo, J., Zhang, P., Makita, J., Blessing, K., Kador, P.F., Orally active multi-functional antioxidants delay cataract formation in streptozotocin (type 1) diabetic and gamma-irradiated rats. PLoS One, 6, 2011, e18980.
213. Richeti, F., Noronha, R.M., Waetge, R.T., de Vasconcellos, J.P., de Souza, O.F., Kneipp, B., Assis, N., Rocha, M.N., Calliari, L.E., Longui, C.A., Monte, O., de Melo, M.B., Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy. Mol. Vis. 13 (2007), 740–745.
214. Richter, M., Guscetti, F., Spiess, B., Aldose reductase activity and glucose-related opacities in incubated lenses from dogs and cats. Am. J. Vet. Res. 63 (2002), 1591–1597.
215. Robison, W.G. Jr., Houlder, N., Kinoshita, J.H., The role of lens epithelium in sugar cataract formation. Exp. Eye Res. 50 (1990), 641–646.
216. Robison, W.G. Jr., Kador, P.F., Kinoshita, J.H., Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science 221 (1983), 1177–1179.
217. Robison, W.G. Jr., Tillis, T.N., Laver, N., Kinoshita, J.H., Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp. Eye Res. 50 (1990), 355–366.
218. Sato, S., Lin, L.R., Reddy, V.N., Kador, P.F., Aldose reductase in human retinal pigment epithelial cells. Exp. Eye Res. 57 (1993), 235–241.
219. Sato, S., Mori, K., Wyman, M., Kador, P.F., Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175. Exp. Eye Res. 66 (1998), 217–222.
220. Sato, S., Takahashi, Y., Wyman, M., Kador, P.F., Progression of sugar cataract in the dog. Invest. Ophthalmol. Vis. Sci. 32 (1991), 1925–1931.
221. Schleicher, E.D., Weigert, C., Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int. Suppl. 77 (2000), S13–S18.
222. Schultz, R.O., Matsuda, M., Yee, R.W., Edelhauser, H.F., Schultz, K.J., Corneal endothelial changes in type I and type II diabetes mellitus. Am. J. Ophthalmol. 98 (1984), 401–410.
223. Segal, S., Another aspect of the galactosemia enigma. Mol. Genet. Metab. 81 (2004), 253–254 author reply 255–257.
224. Shah, V.O., Scavini, M., Nikolic, J., Sun, Y., Vai, S., Griffith, J.K., Dorin, R.I., Stidley, C., Yacoub, M., Vander Jagt, D.L., Eaton, R.P., Zager, P.G., Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J. Clin. Endocrinol. Metab. 83 (1998), 2886–2891.
225. Sharma, P., Vasavada, A.R., Acute transient bilateral diabetic posterior subcapsular cataracts(1). J. Cataract. Refract Surg. 27 (2001), 789–794.
226. Sima, A.A., Pathological definition and evaluation of diabetic neuropathy and clinical correlations. Can. J. Neurol. Sci. 21 (1994), S13–S17.
227. Simpson, R.G., Moshirfar, M., Edmonds, J.N., Christiansen, S.M., Laser in-situ keratomileusis in patients with diabetes mellitus: a review of the literature. Clin. Ophthalmol. 6 (2012), 1665–1674.
228. Skarbez, K., Priestley, Y., Hoepf, M., Koevary, S.B., Comprehensive review of the effects of diabetes on ocular health. Expert Rev. Ophthalmol. 5 (2010), 557–577.
229. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch. Ophthalmol. 108 (1990), 1234–1244.
230. Spielberg, S.P., Shear, N.H., Cannon, M., Hutson, N.J., Gunderson, K., In-vitro assessment of a hypersensitivity syndrome associated with sorbinil. Ann. Intern Med. 114 (1991), 720–724.
231. Suzuki, Y., Atsumi, Y., Matsuoka, K., Suzuki, Y., Nishimaki, K., Ohta, S., Suzuki, Y., Taniyama, M., Suzuki, Y., Muramatsu, T., Suzuki, Y., Acute metabolic cataract as a first manifestation of diabetes mellitus in a 12-year-old girl. Diabetologia 47 (2004), 592–593.
232. Takahashi, Y., Augustin, W., Wyman, M., Kador, P.F., Quantitative analysis of retinal vessel changes in galactose-fed dogs. J. Ocul. Pharmacol. 9 (1993), 257–269.
233. Takahashi, Y., Wyman, M., Ferris, F. 3rd, Kador, P.F., Diabeteslike preproliferative retinal changes in galactose-fed dogs. Archives Ophthalmol. 110 (1992), 1295–1302.
234. Takamura, Y., Kubo, E., Tsuzuki, S., Akagi, Y., Apoptotic cell death in the lens epithelium of rat sugar cataract. Exp. Eye Res. 77 (2003), 51–57.
235. Takamura, Y., Sugimoto, Y., Kubo, E., Takahashi, Y., Akagi, Y., Immunohistochemical study of apoptosis of lens epithelial cells in human and diabetic rat cataracts. Jpn. J. Ophthalmol. 44 (2000), 569–570.
236. van Gerven, J.M., Boot, J.P., Lemkes, H.H., van Best, J.A., Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc. Ophthalmol. 87 (1994), 355–365.
237. Van Heyningen, R., Formation of polyols in the lens of the rat with “sugar” cataract. Nature 184 (1959), 194–195.
238. Vanderveen, D.K., Cataract update 2008: all you need to know about your pediatric cataract patients. Binocul. Vis. Strabismus Q. 23 (2008), 145–158.
239. Varma, S.D., Kinoshita, J.H., The absence of cataracts in mice with congenital hyperglycemia. Exp. Eye Res. 19 (1974), 577–582.
240. Varma, S.D., Schocket, S.S., Richards, R.D., Implications of aldose reductase in cataracts in human diabetes. Invest. Ophthalmol. Vis. Sci. 18 (1979), 237–241.
241. Vedantham, S., Thiagarajan, D., Ananthakrishnan, R., Wang, L., Rosario, R., Zou, Y.S., Goldberg, I., Yan, S.F., Schmidt, A.M., Ramasamy, R., Aldose reductase drives hyperacetylation of Egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals. Diabetes 63 (2014), 761–774.
242. Vinding, T., Nielsen, N.V., Two cases of acutely developed cataract in diabetes mellitus. Acta Ophthalmol. (Copenh) 62 (1984), 373–377.
243. Vinores, S.A., Campochiaro, P.A., Williams, E.H., May, E.E., Green, W.R., Sorenson, R.L., Aldose reductase expression in human diabetic retina and retinal pigment epithelium. Diabetes 37 (1988), 1658–1664.
244. Wahren, J., Larsson, C., C-peptide: new findings and therapeutic possibilities. Diabetes Res. Clin. Pract. 107 (2015), 309–319.
245. Wang, Y., Luk, A.O., Ng, M.C., Pang, C.C., Lam, V., Lee, S.C., Lam, D.S., Choy, K.W., Ma, R.C., So, W.Y., Chan, J.C., Additive effect of aldose reductase Z-4 microsatellite polymorphism and glycaemic control on cataract development in type 2 diabetes. J. Diabetes Complicat. 28 (2014), 147–151.
246. Wang, Y., Ng, M.C., Lee, S.C., So, W.Y., Tong, P.C., Cockram, C.S., Critchley, J.A., Chan, J.C., Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 26 (2003), 2410–2415.
247. Williamson, J.R., Chang, K., Frangos, M., Hasan, K.S., Ido, Y., Kawamura, T., Nyengaard, J.R., Enden, M.v.d., Kilo, C., Tilton, R.G., Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42 (1993), 801–813.
248. Yan, S.F., Ramasamy, R., Schmidt, A.M., The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 106 (2010), 842–853.
249. Yang, B., Millward, A., Demaine, A., Functional differences between the susceptibility Z-2/C-106 and protective Z+2/T-106 promoter region polymorphisms of the aldose reductase gene may account for the association with diabetic microvascular complications. Biochim. Biophys. Acta 1639 (2003), 1–7.
250. Yang, S.K., Xiao, L., Li, J., Liu, F., Sun, L., Oxidative stress, a common molecular pathway for kidney disease: role of the redox enzyme p66Shc. Ren. Fail 36 (2014), 313–320.
251. Yee, R.W., Matsuda, M., Kern, T.S., Engerman, R.L., Edelhauser, H.F., Corneal endothelial changes in diabetic dogs. Curr. Eye Res. 4 (1985), 759–766.
252. Yeh, L.A., Ashton, M.A., The increase in lipid peroxidation in diabetic rat lens can be reversed by oral sorbinil. Metabolism 39 (1990), 619–622.
253. Yokoi, N., Niiya, A., Komuro, A., Yokogaki, S., Naka, H., Awata, T., Honma, Y., Yamada, J., Tei, M., Kinoshita, S., Effects of aldose reductase inhibitor CT-112 on the corneal epithelial barrier of galactose-fed rats. Curr. Eye Res. 16 (1997), 595–599.
254. Zatechka, D.S. Jr., Kador, P.F., Garcia-Castineiras, S., Lou, M.F., Diabetes can alter the signal transduction pathways in the lens of rats. Diabetes 52 (2003), 1014–1022.
255. Zhang, P., Xing, K., Randazzo, J., Blessing, K., Lou, M.F., Kador, P.F., Osmotic stress, not aldose reductase activity, directly induces growth factors and MAPK signaling changes during sugar cataract formation. Exp. Eye Res. 101 (2012), 36–43.
256. Zhang, Z., Xing, K., Randazzo, J., Blessing, K., Lou, M.F., Kador, P.F., Osmotic stress, not aldose reductase activity, directly induces growth factors and MAPK signaling changes during sugar cataract formation. Exp. Eye Res. 101 (2012), 36–43.
257. Zou, X.-M., Zhao, H.-L., Song, H.-J., Lu, J.-M., C-Y, P., Association of the Z-2 and 2 allele of aldose reductase gene with its erythrocyte activity and diabetic microangiopathy in Chinese with type 2 diabetes. Diabetes Res. Clin. Pract. 57:Suppl. 1 (2002), S27–S28.